InVivo Therapeutics Holdings Corp. (NASDAQOTH:NVIV)

CAPS Rating: 1 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar TSIF (99.96) Submitted: 11/18/2014 7:26:49 PM : Underperform Start Price: $1.37 NVIV Score: +14.13

Greater fools have taken a beating on their InVivo CAPS short, so I'll be in good company if this continues even after a 150% one month gain.

"development stage biomaterials and biotechnology " MIT and Spinal Cords, not a fly by night.

ONE patient, pilot study. Focus clearly safety, but even one patient showing effectively would be helpful. Five patients total planned.

Long haul, (end of 2015 for this batch of 5), Three month stagger, 6-12 months further monitoring = almost 2 years on this pilot. Moderate funding after stock issue at $1.15. (Estimated funding to March 2016).

Short term retrace, could be a long term sleeper, but must prove safety, affectivity, why it's a better option, insurance reimbursement, etc....

Recs

0
Member Avatar ozzie (99.95) Submitted: 10/25/2014 11:52:08 PM : Underperform Start Price: $0.90 NVIV Score: -27.25

http://pennystockipedia.com/pump-and-dump-watch-list/

Recs

0
Member Avatar SmartAce (99.88) Submitted: 10/20/2014 4:23:48 PM : Underperform Start Price: $0.69 NVIV Score: -63.89

The ratio of people to cake is too big.
Milton

Recs

2
Member Avatar jed71 (62.95) Submitted: 10/17/2014 1:52:50 PM : Underperform Start Price: $0.69 NVIV Score: -64.34

There’s lots of information out there on this stock already so I don’t feel it’s necessary for me to post a massive pitch. I encourage you to go read ZZLangerhans’ previous pitches and blogs about this stock as they do contain some key information that might be helpful. The stock has recently rebounded from its lows due to a recent press release:

“InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.”

It’s somewhat understandable that it bounced higher given the new CEO called it a “major milestone not only for the company, but also for the field of traumatic SCI.” That’s great and everything, but they are a very, very long ways off from having a viable, FDA-approved product. Shareholders have completely overreacted to what I believe is tepid news. Here's some key information I found:

“InVivo Therapeutics Corporation (?InVivo?) was incorporated on November 28, 2005 under the laws of the State of Delaware. On October 26, 2010, InVivo completed a reverse merger transaction (the Merger?) with InVivo Therapeutics Holdings Corp. (formerly Design Source, Inc.) (?ITHC?), a publicly traded company incorporated under the laws of the State of Nevada. InVivo became a wholly owned subsidiary of ITHC, which continues to operate the business of InVivo. InVivo is a life sciences company focused on the development and commercialization of both novel drug delivery technologies as well as biopolymer devices for the treatment of spinal cord injuries and other nervous system conditions. The biopolymer devices are designed to protect and repair damaged tissue and to deliver drugs and other agents, including proteins. The post-merger combination of ITHC and InVivo is referred to throughout these notes to consolidated financial statements as the Company.”

“In August 2013, Frank Reynolds, our former Chief Executive Officer and Chief Financial Officer, resigned from the Company, and Michael J. Astrue was appointed Interim Chief Executive Officer. Sean Moran, who was appointed Acting Chief Financial Officer following the resignation of Mr. Reynolds, subsequently resigned from the Company in September 2013. Shortly thereafter, Gregory D. Perry was appointed Interim Chief Financial Officer.”

“Since its inception, InVivo has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. Accordingly, InVivo is considered to be in the development stage.”

So you can easily see where this was reverse merged into existence. Anyone interested what the business plan was in 2005? Well, here you go (from a very early 2006 10-Q): “Part of our marketing program includes sourcing out and identifying interior designers and individual consumers who may become potential buyers of commercial upholstery, drapery, bedspread, panel, and wall-covering fabrics from our website. The process of sourcing out suppliers includes identifying manufacturers, large and small by research into existing databases via the internet and research in trade magazines and directories.”

So in early 2006, the company was attempting to raise $50K in capital to sell drapes. And now they are attempting to sell spinal scaffold to patients of traumatic spinal injuries? That is one heck of a leap. Take a look at the second copy/paste from the 10-Q above; the CEO and CFO both resigned. Guess who owns a ton of shares and has been selling them on a pretty regular basis? I’ll give you three guesses and the first two don’t count.

The third copy/paste above is enlightening for a number of reasons. Note the company has been around since 2005 and yet are still in the development stage? Does this raise a huge red flag for anyone else? I don’t see any revenue back through inception but I do see lots of reasons to avoid this stock like it’s contracted the black plague.

Recs

0
Member Avatar 007mercucio (< 20) Submitted: 9/12/2013 10:37:30 AM : Outperform Start Price: $1.44 NVIV Score: -39.38

cured monkeys of spinal damage induced paralysis - next step, humans
stock at an all time low
heavy accumulation indicates possible buyout target

Recs

0
Member Avatar kentinc (54.35) Submitted: 5/13/2013 2:38:49 PM : Outperform Start Price: $2.94 NVIV Score: -86.13

The big IF is successfully navigating clinical human trials. If it does so then this has massive upside potential.

Recs

0
Member Avatar holytea7 (< 20) Submitted: 3/18/2013 9:45:48 PM : Outperform Start Price: $2.31 NVIV Score: -81.75

Next Top Dog and First Mover in medical device company.

Results 1 - 7 of 7

Featured Broker Partners


Advertisement